Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This study is a Phase Ib, open label, multi-center study of to evaluate the safety and
efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion
mutations.